The
nuclear receptor PPARγ regulates adipogenesis and plays a central role in
lipid and
glucose homeostasis, and is the molecular target of the
glitazones (TZDs),
therapeutics used to treat
insulin resistance and type-2 diabetes (T2D). Although the TZDs, which are PPARγ agonists, demonstrated robust clinical efficacy in T2D, their use has been hampered by an array of untoward side effects. Paradoxically, partial agonists (e.g. MRL24), antagonists (e.g.
SR1664), and inverse agonists (e.g. SR10171 and
SR2595), possess similar
insulin-sensitizing efficacy as the TZDs in obese diabetic mice. Given the unique pharmacology of these modulators, we sought to identify the components of the PPARγ transcriptional complex that is regulated by these
ligands. To achieve this, we employed subcellular fractionation of adipocytes combined with either trapping of the receptor complex on biotinylated
DNA oligonucleotide, or classical immunoprecipitation. Tandem mass spectrometry analysis revealed unique, partially overlapping, compound- and subcellular compartment-specific complexes. Components of these interactomes are putative coregulators of PPARγ. Interestingly, complexes isolated in the cytosol contain sets of
proteins involve in cellular assembly and extracellular matrix. Furthermore, the interactome observed for cytosolic non-
DNA bound receptor was distinct from that observed from nuclear
chromatin associated PPARγ, suggesting cellular compartment-specific roles for this receptor.